Wilms tumor gene(WT1)expression in leukemic and normal hematopoietic stem cells.

肾母细胞瘤基因（WT1）在白血病和正常造血干细胞中的表达。

• 批准号: 09671110
• 负责人: OGAWA Hiroyasu
• 金额: $ 1.92万
• 依托单位: Osaka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1997
• 资助国家: 日本
• 起止时间: 1997 至 1998
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-09671110/
• 关键词: WT1 gene; minimal residual disease; hematopoietic stem cell; Leukemia; WT1; 微小残存白血病; 骨髄移植

As Wilms' tumor gene (WT1) is highly expressed in bone marrow and blood specimens in all patients with leukemia, minimal residual leukemia (MRD) can be estimated by the quanlitation of the gene expression with RT-PCR method.Low level expression of WT1 gene in CD34 fraction of normal bone marrow cells may result in reducing the sensitivity of the detection of MRD by WT1 assay.In allogeneic bone marrow transplantation setting, CD34 fraction and WT1 levels of the bone marrow cells were monitored in patients with lymphoma who did not expressed WT1 gene.As a result, the percentage of the normal CD34 fraction and WT1 gene expression level derived from the fraction concurrently decreased to less than one tenth.On the other hand, WT1 gene expression in leukemic cells is increased in relapse.Therefore, this MRD detection system is very useful for the diagnosis of early molecular relapse in patients with leukemia who were treated with bone marrow transplantation.

由于Wilms肿瘤基因(WT1)在所有白血病患者的骨髓和血液标本中都有高表达，因此可以通过RT-PCR方法定量检测WT1基因的表达来判断微小残留白血病(MRD)。正常骨髓细胞中WT1基因的低水平表达可能导致WT1检测MRD的敏感性降低。在异基因骨髓移植的背景下，对未表达WT1基因的淋巴瘤患者的骨髓细胞CD34部分和WT1水平进行了监测。结果表明，WT1基因在正常骨髓细胞中的低水平表达可能导致WT1基因检测的敏感性降低。CD34组分的正常百分率和WT1基因表达水平同时下降到十分之一以下，而白血病细胞中WT1基因的表达在复发时增加，因此，该MRD检测系统对于诊断接受骨髓移植治疗的白血病患者的早期分子复发非常有用。

项目成果

Sako M.,et al.: "Abnormal expression of the Wilms'tumor gene WT1 in juvenile chronic myeloid leukemia and infantile monosomy 7 syndrome." Leukemia Reseaech. in press.

Sako M. 等人：“幼年慢性粒细胞白血病和婴儿 7 号单体综合征中肾母细胞瘤基因 WT1 的异常表达。”

Tamaki H,Ogawa H,Ohyashiki K,Oyhashiki JH, Iwama H,Inoue K,Soma T,Oka Y,Tatekawa T,Oji Y,Tsuboi A,Kim EH,Kawakami M,Fuchigami K,Tomonaga M,Toyama K,Aozasa K,Kishimoto T,and Sugiyama H.: "The Wilms' tumor gene WT1 is a good marker for diagnosis of disease

Tamaki H、Okawa H、Ohyashiki K、Oyhashiki JH、Iwama H、Inoue K、Soma T、Oka Y、Tatekawa T、Oji Y、Tsuboi A、Kim EH、Kawakami M、Fuchigami K、Tomonaga M、Toyama K、Aozasa K

Inoue K.: "Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells." Blood. (in press.).

Inoue K.：“维尔姆斯肿瘤基因 (WT1) 与造血祖细胞中的分化诱导信号竞争。”

Sako M.,et al.: "Abnormal expression of the Wilms' tumor gene WT1 in juvenile chronic myeloid leukemia and infantile monosomy 7 syndrome." Leukemia Research,. (in press.).

Sako M. 等人：“幼年慢性粒细胞白血病和婴儿 7 号单体综合征中肾母细胞瘤基因 WT1 的异常表达。”

Ogawa H,,et al.: "Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: Importance of the monitoring of minimal residual disease by WT1 assay." Bo

Okawa H 等人：“对接受同种异体骨髓移植治疗的急性髓性白血病患者在分子复发时成功进行供体白细胞输注：通过 WT1 检测监测微小残留病的重要性。”